Evicenter
P&T meetings

Emiltatug ledadotin

Adenoid cystic carcinoma with solid histology or high-grade transformation

Also known as Emi-Le, XMT-1660
Manufacturer
Servier
Regulatory submission
Not announced
Launch
Not announced
125 sources

Section 6 of 6

References

125 sources

  1. ACCRF (2025) (opens in a new tab)
  2. ADC Review (2025) (opens in a new tab)
  3. Airoldi et al. (2001) (opens in a new tab)
  4. Amit et al. (2015) (opens in a new tab)
  5. Ammad Ud Din and Shaikh (2023) (opens in a new tab)
  6. Bedell et al. (2024) (opens in a new tab)
  7. Bölek et al. (2025) (opens in a new tab)
  8. Boyle et al. (2020) (opens in a new tab)
  9. Caspani et al. (2025) (opens in a new tab)
  10. ClinicalTrials.gov NCT03691207 (opens in a new tab)
  11. ClinicalTrials.gov NCT04883671 (opens in a new tab)
  12. ClinicalTrials.gov NCT05123482 (opens in a new tab)
  13. ClinicalTrials.gov NCT05194072 (opens in a new tab)
  14. ClinicalTrials.gov NCT05377996 (opens in a new tab)
  15. ClinicalTrials.gov NCT07162480 (opens in a new tab)
  16. CMS (2025) (opens in a new tab)
  17. Coca-Pelaz et al. (2015) (opens in a new tab)
  18. CURE (2026) (opens in a new tab)
  19. Day One Biopharmaceuticals (2025) (opens in a new tab)
  20. Day One Biopharmaceuticals acquisition completion announcement (2026) (opens in a new tab)
  21. Day One Biopharmaceuticals acquisition presentation (2025) (opens in a new tab)
  22. Day One Biopharmaceuticals Form 10-K (2026) (opens in a new tab)
  23. Day One Biopharmaceuticals Form 8-K (2026) (opens in a new tab)
  24. Day One Biopharmaceuticals J.P. Morgan Healthcare Conference presentation (2026) (opens in a new tab)
  25. Day One Biopharmaceuticals presentation (2026) (opens in a new tab)
  26. Day One Biopharmaceuticals Schedule 14D-9 (2026) (opens in a new tab)
  27. de Sousa and Ferrarotto (2024) (opens in a new tab)
  28. de Sousa et al. (2023) (opens in a new tab)
  29. DelveInsight (2026) (opens in a new tab)
  30. Ellington et al. (2012) (opens in a new tab)
  31. FDA Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics guidance (2018) (opens in a new tab)
  32. Ferrand et al. (2024) (opens in a new tab)
  33. Ferrarotto et al. (2017) (opens in a new tab)
  34. Ferrarotto et al. (2021) (opens in a new tab)
  35. Ferrarotto et al. (2023) (opens in a new tab)
  36. Ferrarotto et al. (2024) (opens in a new tab)
  37. Ferrarotto et al. (2026) (opens in a new tab)
  38. Galot and Machiels (2026) (opens in a new tab)
  39. Geiger et al. (2021) (opens in a new tab)
  40. Girelli et al. (2017) (opens in a new tab)
  41. GSK BEHOLD-1 data announcement (2026) (opens in a new tab)
  42. Guideline Central (2021) (opens in a new tab)
  43. Haigh et al. (2025) (opens in a new tab)
  44. Hamilton et al. (2025) (opens in a new tab)
  45. Hanna et al. (2020) (opens in a new tab)
  46. Hanna et al. (2023a) (opens in a new tab)
  47. Hanna et al. (2023b) (opens in a new tab)
  48. Hanna et al. (2024) (opens in a new tab)
  49. Hanna et al. (2026a) (opens in a new tab)
  50. Hanna et al. (2026b) (opens in a new tab)
  51. Ho et al. (2013) (opens in a new tab)
  52. Ho et al. (2016) (opens in a new tab)
  53. Ho et al. (2019) (opens in a new tab)
  54. Ho et al. (2026) (opens in a new tab)
  55. Hoff et al. (2024) (opens in a new tab)
  56. Hoff et al. (2025a) (opens in a new tab)
  57. Hoff et al. (2025b) (opens in a new tab)
  58. Hoff et al. (2026) (opens in a new tab)
  59. IMARC Group (2026) (opens in a new tab)
  60. Ishida et al. (2020) (opens in a new tab)
  61. Jacobson et al. (2012) (opens in a new tab)
  62. Jensen and Debus (2019) (opens in a new tab)
  63. Kang et al. (2021) (opens in a new tab)
  64. Kang et al. (2025) (opens in a new tab)
  65. Keam et al. (2015) (opens in a new tab)
  66. Kim et al. (2024) (opens in a new tab)
  67. Kinneer et al. (2023) (opens in a new tab)
  68. Laurie et al. (2011) (opens in a new tab)
  69. Locati et al. (2016) (opens in a new tab)
  70. Locati et al. (2019) (opens in a new tab)
  71. Locati et al. (2020) (opens in a new tab)
  72. Lombardi et al. (2022) (opens in a new tab)
  73. Ma et al. (2024) (opens in a new tab)
  74. Meric-Bernstam et al. (2024) (opens in a new tab)
  75. Mersana Therapeutics ASCO 2025 announcement (2025) (opens in a new tab)
  76. Mersana Therapeutics ASCO 2025 presentation (2025) (opens in a new tab)
  77. Mersana Therapeutics Day One merger announcement (2025) (opens in a new tab)
  78. Mersana Therapeutics Fast Track announcement (2025) (opens in a new tab)
  79. Mersana Therapeutics Form 10-K (2025) (opens in a new tab)
  80. Mersana Therapeutics Form 10-Q (2025) (opens in a new tab)
  81. Mersana Therapeutics Form 8-K (2025) (opens in a new tab)
  82. Mersana Therapeutics initial clinical data announcement (2025) (opens in a new tab)
  83. Mersana Therapeutics initial phase 1 data presentation (2025) (opens in a new tab)
  84. Mersana Therapeutics Schedule 14D-9 (2025) (opens in a new tab)
  85. Michaeli and Michaeli (2023) (opens in a new tab)
  86. Mitani et al. (2010) (opens in a new tab)
  87. Morita et al. (2021) (opens in a new tab)
  88. NCCN Guidelines Head and Neck Cancers (opens in a new tab)
  89. Nguyen et al. (2023) (opens in a new tab)
  90. OncLive (2026) (opens in a new tab)
  91. OncLive Hanna interview (2026) (opens in a new tab)
  92. Pal et al. (2025) (opens in a new tab)
  93. Persson et al. (2009) (opens in a new tab)
  94. Pfister et al. (2020) (opens in a new tab)
  95. Rahouma et al. (2024) (opens in a new tab)
  96. Rai et al. (2025) (opens in a new tab)
  97. Ran et al. (2021) (opens in a new tab)
  98. Rao et al. (2026) (opens in a new tab)
  99. Research and Markets (2026) (opens in a new tab)
  100. Sahara et al. (2021) (opens in a new tab)
  101. Seethala et al. (2007) (opens in a new tab)
  102. Seethala et al. (2011) (opens in a new tab)
  103. Servier acquisition completion announcement (2026) (opens in a new tab)
  104. Servier and Day One Biopharmaceuticals (2026) (opens in a new tab)
  105. Servier ASCO 2026 presentations announcement (2026) (opens in a new tab)
  106. Servier ASCO 2026 results announcement (2026) (opens in a new tab)
  107. Servier ASCO 2026 results announcement (2026) (opens in a new tab)
  108. Servier breakthrough therapy designation announcement (2026) (opens in a new tab)
  109. Servier breakthrough therapy designation announcement (2026) (opens in a new tab)
  110. Singer et al. (2025) (opens in a new tab)
  111. Siqueira et al. (2025) (opens in a new tab)
  112. Skálová et al. (2021) (opens in a new tab)
  113. Skálová et al. (2022) (opens in a new tab)
  114. Szanto et al. (1984) (opens in a new tab)
  115. Tchekmedyian et al. (2019) (opens in a new tab)
  116. Thomson et al. (2015) (opens in a new tab)
  117. Toader et al. (2023) (opens in a new tab)
  118. van Herpen et al. (2022) (opens in a new tab)
  119. van Weert et al. (2015) (opens in a new tab)
  120. van Weert et al. (2017) (opens in a new tab)
  121. Vos et al. (2023) (opens in a new tab)
  122. Wang et al. (2026) (opens in a new tab)
  123. Zhang et al. (2022) (opens in a new tab)
  124. Zhu et al. (2021) (opens in a new tab)
  125. Zupancic et al. (2023) (opens in a new tab)